Related Experiment Video
Updated: Mar 23, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Designing therapeutic cancer vaccines by mimicking viral infections
Hussein Sultan1,2, Valentyna I Fesenkova1, Diane Addis1
1Augusta University GRU Cancer Center, CN-4121, 1410 Laney Walker Boulevard, Augusta, GA, 30912, USA.
Abstract:
The design of efficacious and cost-effective therapeutic vaccines against cancer remains both a research priority and a challenge. For more than a decade, our laboratory has been involved in the development of synthetic peptide-based anti-cancer therapeutic vaccines. We first dedicated our efforts in the identification and validation of peptide epitopes for both CD8 and CD4 T cells from tumor-associated antigens (TAAs). Because of suboptimal immune responses and lack of therapeutic benefit of peptide vaccines containing these epitopes, we have focused our recent efforts in optimizing peptide vaccinations in mouse tumor models using numerous TAA epitopes. In this focused research review, we describe how after taking lessons from the immune system's way of dealing with acute viral infections, we have designed peptide vaccination strategies capable of generating very high numbers of therapeutically effective CD8 T cells. We also discuss some of the remaining challenges to translate these findings into the clinical setting.
Insights
Developing effective cancer vaccines is crucial. This research optimized peptide vaccinations in mice, mimicking viral infection responses to generate potent CD8 T cells for cancer therapy, addressing current challenges.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Designing effective and affordable cancer therapeutic vaccines is a significant research challenge.
- Previous peptide vaccines targeting tumor-associated antigens (TAAs) showed suboptimal immune responses and limited therapeutic benefits.
- Our lab has over a decade of experience in developing synthetic peptide-based anti-cancer vaccines.
Purpose of the Study:
- To optimize peptide vaccination strategies for generating therapeutically effective CD8 T cells against cancer.
- To leverage insights from the immune system's response to viral infections for improved vaccine design.
- To review progress and discuss challenges in translating preclinical findings to clinical application.
Main Methods:
- Identification and validation of peptide epitopes from TAAs for CD8 and CD4 T cell recognition.
- Optimization of peptide vaccination protocols in mouse tumor models using various TAA epitopes.
- Designing vaccination strategies inspired by the immune response to acute viral infections.
Main Results:
- Developed novel peptide vaccination strategies capable of inducing high numbers of therapeutically effective CD8 T cells.
- Demonstrated the potential of optimized peptide vaccines in preclinical mouse models.
- Gained insights into generating robust T cell responses relevant for cancer immunotherapy.
Conclusions:
- Optimized peptide vaccination strategies, informed by viral immunity, can generate potent anti-cancer CD8 T cell responses.
- Significant progress has been made in enhancing the efficacy of peptide-based cancer vaccines.
- Further research is needed to overcome challenges in translating these findings to human clinical trials.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies